CONTEXT: Age-related macular degeneration is a prevalent disease of aging that may cause irreversible vision loss, disability, and depression. The latter is rarely recognized or treated in ophthalmologic settings. OBJECTIVE: To determine whether problem-solving treatment can prevent depressive disorders in patients with recent vision loss. DESIGN: Randomized, controlled trial. SETTING:Outpatient ophthalmology offices in Philadelphia, Pennsylvania. PATIENTS: Two hundred six patients aged 65 years or older with recent diagnoses of neovascular age-related macular degeneration in one eye and pre-existing age-related macular degeneration in the fellow eye. INTERVENTION: Patients were randomly assigned to problem-solving treatment (n = 105) or usual care (n = 101). Problem-solving treatment therapists delivered 6 sessions during 8 weeks in subjects' homes. MAIN OUTCOME MEASURES: Outcomes were assessed at 2 months for short-term effects and 6 months for maintenance effects. These included DSM-IV-defined diagnoses of depressive disorders, National Eye Institute Vision Function Questionnaire-17 scores, and rates of relinquishing valued activities. RESULTS: The 2-month incidence rate of depressive disorders in problem-solving-treated subjects was significantly lower than controls (11.6% vs 23.2%, respectively; odds ratio, 0.39; 95% confidence interval, 0.17-0.92; P = .03). Problem-solving treatment also reduced the odds of relinquishing a valued activity (odds ratio, 0.48; 95% confidence interval, 0.25-0.96; P = .04). This effect mediated the relationship between treatment group and depression. By 6 months, most earlier observed benefits had diminished, though problem-solving treatment subjects were less likely to suffer persistent depression (chi2(1,3) = 8.46; P = .04). CONCLUSIONS:Problem-solving treatment prevented depressive disorders and loss of valued activities in patients with age-related macular degeneration as a short-term treatment, but these benefits were not maintained over time. Booster or rescue treatments may be necessary to sustain problem-solving treatment's preventative effect. This study adds important new information to the emerging field of enhanced-care models to prevent or treat depression in older persons. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00042211.
RCT Entities:
CONTEXT: Age-related macular degeneration is a prevalent disease of aging that may cause irreversible vision loss, disability, and depression. The latter is rarely recognized or treated in ophthalmologic settings. OBJECTIVE: To determine whether problem-solving treatment can prevent depressive disorders in patients with recent vision loss. DESIGN: Randomized, controlled trial. SETTING:Outpatient ophthalmology offices in Philadelphia, Pennsylvania. PATIENTS: Two hundred six patients aged 65 years or older with recent diagnoses of neovascular age-related macular degeneration in one eye and pre-existing age-related macular degeneration in the fellow eye. INTERVENTION: Patients were randomly assigned to problem-solving treatment (n = 105) or usual care (n = 101). Problem-solving treatment therapists delivered 6 sessions during 8 weeks in subjects' homes. MAIN OUTCOME MEASURES: Outcomes were assessed at 2 months for short-term effects and 6 months for maintenance effects. These included DSM-IV-defined diagnoses of depressive disorders, National Eye Institute Vision Function Questionnaire-17 scores, and rates of relinquishing valued activities. RESULTS: The 2-month incidence rate of depressive disorders in problem-solving-treated subjects was significantly lower than controls (11.6% vs 23.2%, respectively; odds ratio, 0.39; 95% confidence interval, 0.17-0.92; P = .03). Problem-solving treatment also reduced the odds of relinquishing a valued activity (odds ratio, 0.48; 95% confidence interval, 0.25-0.96; P = .04). This effect mediated the relationship between treatment group and depression. By 6 months, most earlier observed benefits had diminished, though problem-solving treatment subjects were less likely to suffer persistent depression (chi2(1,3) = 8.46; P = .04). CONCLUSIONS: Problem-solving treatment prevented depressive disorders and loss of valued activities in patients with age-related macular degeneration as a short-term treatment, but these benefits were not maintained over time. Booster or rescue treatments may be necessary to sustain problem-solving treatment's preventative effect. This study adds important new information to the emerging field of enhanced-care models to prevent or treat depression in older persons. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00042211.
Authors: Emily Feinberg; Rachel Stein; Yaminette Diaz-Linhart; Lucia Egbert; William Beardslee; Mark T Hegel; Michael Silverstein Journal: Fam Community Health Date: 2012 Jan-Mar
Authors: Barry W Rovner; Robin J Casten; Mark T Hegel; Robert W Massof; Benjamin E Leiby; William S Tasman Journal: Contemp Clin Trials Date: 2010-10-23 Impact factor: 2.226
Authors: Kim van Zoonen; Claudia Buntrock; David Daniel Ebert; Filip Smit; Charles F Reynolds; Aartjan T F Beekman; Pim Cuijpers Journal: Int J Epidemiol Date: 2014-04 Impact factor: 7.196
Authors: Charles F Reynolds; Pim Cuijpers; Vikram Patel; Alex Cohen; Amit Dias; Neerja Chowdhary; Olivia I Okereke; Mary Amanda Dew; Stewart J Anderson; Sati Mazumdar; Frank Lotrich; Steven M Albert Journal: Annu Rev Public Health Date: 2012-04 Impact factor: 21.981
Authors: Charles F Reynolds; Stephen B Thomas; Jennifer Q Morse; Stewart J Anderson; Steven Albert; Mary Amanda Dew; Amy Begley; Jordan F Karp; Ariel Gildengers; Meryl A Butters; Jacqueline A Stack; John Kasckow; Mark D Miller; Sandra C Quinn Journal: Psychiatr Serv Date: 2014-06-01 Impact factor: 3.084